Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. increased its price target for Gilead Sciences from $135.00 to $145.00, indicating a potential upside of 28.84% from the previous close.
• Gilead Sciences has received multiple upgrades from analysts, with three rating it as a Strong Buy and eighteen categorizing it as a Buy.
• The company reported earnings of $2.01 per share for the last quarter, exceeding estimates and posting a revenue of $7.08 billion, which was a 1.4% year-over-year increase.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective increased by research analysts at JPMorgan Chase & Co. from $135.00 to $145.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s target price indicates a potential upside of 28.84% from the company's previous close.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $116.04.

Gilead Sciences Stock Down 1.8%

Shares of NASDAQ GILD opened at $112.54 on Tuesday. The stock has a market capitalization of $139.64 billion, a P/E ratio of 22.42, a P/E/G ratio of 0.78 and a beta of 0.36. The company has a 50-day moving average price of $114.05 and a 200-day moving average price of $110.06. Gilead Sciences has a 1 year low of $81.83 and a 1 year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 76,500 shares of company stock worth $8,765,395 in the last quarter. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds have recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $215,000. Zurich Insurance Group Ltd FI grew its position in Gilead Sciences by 232.1% in the 4th quarter. Zurich Insurance Group Ltd FI now owns 908,894 shares of the biopharmaceutical company's stock valued at $83,955,000 after buying an additional 635,209 shares during the last quarter. Waverly Advisors LLC grew its position in Gilead Sciences by 8.6% in the 4th quarter. Waverly Advisors LLC now owns 29,181 shares of the biopharmaceutical company's stock valued at $2,695,000 after buying an additional 2,320 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Gilead Sciences by 15.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock valued at $1,130,117,000 after buying an additional 1,605,730 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.